Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipoprotein Cholesterol (<55mg/dL) --

-- Findings Underscore that IPE Can Be an Effective Complementary Therapy with LDL-C Lowering Therapies to Further Improve Cardiovascular Outcomes and Save Lives --